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This study aimed at exploring the method of secretory expression of hepatitis B virus L gene and 
Mycobacterium tuberculosis Ag85B fusion gene in Pichia pastoris GS115, and preliminary tests of L-
Ag85B fusion protein immunoreactivity. The hepatitis B Virus genome extracted from HBsAg positive 
serum and genome of M. tuberculosis H37Rv was used as template to amplify L and Ag85B gene. L-
Ag85B fusion gene was cloned into vector pPICZαC and the expression plasmid pPICZαC-L-Ag85B was 
constructed. After linearization, the plasmid was transformed into P. pastoris GS115 by electroporation. 
SDS-PAGE and Western blot were used to analyze the expression of protein. The purified fusion protein 
L-Ag85B was respectively assayed with serum containing anti-HBsAg or anti-Ag85B by ELISA. The 
recombinant vector was confirmed by sequencing and enzyme digestion. The results of SDS-PAGE and 
Western blot showed that the recombinant protein was induced by methanol and stably expressed in P. 
pastoris, while it has specific reaction with the serum containing anti-HbsAg or anti-Ag85B. However, 
the successful construction of a recombinant yeast expression vector containing gene coding L protein 
and Ag85B gene, and expressed in P. pastoris, lays a foundation for further researches on 
immunogenicity and immune protection by the new type of Hepatitis B- Tuberculosis combined 
vaccine.  
 






Hepatitis B (HB), caused by hepatitis B virus (HBV), and 
tuberculosis (TB) caused by Mycobacterium tuberculosis 
(MTB), are very serious infectious diseases. One-thirds of 
the world’s 6.0 billion population have been infected with 
HBV or MTB (Parida and Kaufmann, 2010; Poorolajal et 
al., 2010). The HBV vaccine applied at present is 
primarily composed of HBsAg (S protein) expressed by 
Chinese hamster ovary cells (CHO cells) and beer yeast. 
It has been found in vaccination that there are still 10 to 
20% of the population who are unresponsive or weakly 
responsive to the HBV vaccine, or who even do not 
produce antibodies at all (Kubba et al., 2003; Jin et al., 
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to prevent TB, has been widely used in neonatal 
vaccination for nearly 100 years, yet its protection rate is 
only about 50% (Kaufmann et al., 2010). The gastro-
intestinal mucosa and broken skin are also an important 
route of transmitting tuberculosis besides the respiratory 
tract. Along with migration and HIV infection, some new, 
easily-spreading TB strains and multiple drug resistant 
strains deteriorate the efficacy of traditional anti-TB drugs 
(Kaufmann et al., 2010; Okada and Kita, 2010). It is very 
likely that HBV and TB may become endemic in the 
immunized population and cause new public problems. 
Therefore, the development of a novel vaccine superior 
to the yeast HBsAg and BCG vaccines is urgently 
needed. 
In this study, we constructed vector pPICZαC-L-Ag85B 
for the expression of a fusion between the HBV L antigen 
and the MTB Ag85B gene. We successfully expressed 





to further study the immune response and immune 
protection of the HB and MTB combined vaccine. 
 
 
MATERIALS AND METHODS  
 
The following materials, MTB H37Rv and E. coli Top 10, were 
obtained from the Department of Microbiology and Immunology of 
the Medical College of Jinan University, while P. pastoris GS115 
and pPICZαC were obtained from Invitrogen, Shanghai, China. 
HbsAg positive serum (serum of hepatitis B patients), anti-HbsAg 
(Hepatitis B surface antigen) positive serum, that is, serum of 
convalescent hepatitis B patients and anti-Ag85B positive serum 
(serum of MTB patients), were obtained from the First Affiliated 
Hospital of Jinan University. The M. tuberculosis genomic DNA 
extraction kit was from Shanghai DOBIO Company (Shanghai, 
China). Ex Taq DNA polymerase, T4 DNA ligase, restriction 
enzymes KpnI, EcoRI, HindIII and SacI, DNA marker, Plasmid mini 
Kit and Gel Extraction Kit were obtained from TAKARA (Dalian, 
China). The target genes were sequenced by Sangon Biological 
Engineering Technology and Service Co. Ltd (Shanghai, China). 
Mouse anti-human HBsAg monoclonal antibody was purchased 
from Beijing Biosynthesis Biotechnology (Beijing, China) and rabbit 
anti-Ag85B monoclonal antibody was from Abcam Company 
(Shanghai, China). However, Ni-Agarose Resin for 6x His-Tagged 
Proteins were from CWBIO (Beijing, China).  
 
 
PCR amplification of the HBV L and MTB Ag85B genes  
 
Two pairs of primers were designed based on the sequence of HBV 
L (GI: 157091234) and MTB Ag85B (GI: 6469794). HBV L gene 
sense primer P1, 5’- TATGAATTCAATGGGAGGTTGGTCTT 
CCAAA-3’, which contains an EcoRI site and the translation 
initiation codon; and anti-sense primer P2, 5’-
GGCGGAAGCTTAATGTATACCCAAAGAC-3’, which primes at the 
3’-terminus of the HBV L gene, but omits the translation termination 
codon. P2 contains a HindIII site. Hepatitis B DNA was extracted 
from a hepatitis B surface antigen positive serum by using phenol / 
chloroform extraction methods, and the DNA was used as the 
template to amplify HBV L. The PCR reaction was carried out as 
follows: 95°C for 10 min; 95°C for 50 s; 56°C for 50 s; 72°C for 1 
min with a total of 35 cycles; and an additional extension step of 10 
min at 72°C which was added at the end. 
MTB Ag85B gene P3 (sense primer):  5’-
TATAAGCTTGGATCCGGAGGTTCATTCTCCCGGCCGGGGCTG-
3’ includes a HindIII site and a linker sequence, while P4 (anti-
sense primer):  5’-AATGGTACCATGCCGGCGCCTAACGAAC-3’ 
includes a KpnI site and omits the translation termination codon. 
The whole genome was extracted from MTB H37Rv by a M. 
tuberculosis genomic DNA extraction kit (DOBIO, Shanghai, China), 
and was used as a template to amplify MTB Ag85B. The reaction 
conditions were at 94°C for 5 min, 94°C for 45 s, 52°C for 45 s and 
72°C for 60 s, after 30 cycles of amplification, and finally at 72°C for 
10 min. The HBV L and MTB Ag85B PCR fragments were purified 
by gel extraction. 
 
 
Construction of the pPICZαC-L-Ag85B plasmid 
 
The purified HBV L and MTB Ag85B PCR products were digested 
with EcoRI / HindIII and KpnI / HindIII, respectively. Both fragments 
were then fused and inserted into the vector pPICZαC which had 
been cut with EcoRI and KpnI, by ligation with T4 DNA ligase. The 
resulting expression plasmid was named as pPICZαC-L-Ag85B. 
The plasmid was transformed into freshly prepared calcium chloride 
competent   E. coli TOP10  cells, and  the  transformed  cells   were  




spread on the LLB (1% Low Salt LB and tryptone; 0.5% yeast 
extract; 0.5% Nacl; PH 7.0) plates containing 25 µg/mL Zeocin. The 
recombinant plasmid pPICZαC-L-Ag85B was isolated from the 
selected positive transformants and confirmed by PCR, restriction 
analysis and sequencing.  
 
 
Yeast transformation and selection 
 
Competent P. pastoris strain GS115 was prepared. The plasmids 
pPICZαC-L-Ag85B was linearized with SacI, and then transformed 
into competent P. pastoris GS115 by electroporation according to 
the P. pastoris transformation instruction manual (Invitrogen, USA). 
Positive transformants were selected on YPDS medium (Yeast 
extract peptone dextrose medium, with yeast extract 1%; peptone 
2%; dextrose 2%; and sorbitol 1 M) containing 100 µg/mL zeocin. 
The Mut+-phenotype was confirmed for both yeasts on MDH 
(Minimal Dextrose Medium+Histidine, YNB 1.34%; biotin 0.004%; 
dextrose 2%; histidine 0.004%) (YNB, 1.34% Yeast Nitrogen Base 
with Ammonium Sulfate without Amino Acids, biotin 0.002%; 
histidine 0.04%; dextrose 2%; methanol 0.5%; glycerol 1%; 0.1 M 
potassium phosphate buffer, PH 6.0) and MMH (Minimal Menthanol 
Medium+ Histidine, YNB 1.34%; biotin 0.004%; menthanol 0.5%; 
histidine 0.004%) plates following the manufacturer’s instructions. 
 
 
Identification of recombinant yeast by PCR 
 
Taking the extracted yeast genome as a template, positive 
transformants were analyzed by PCR with P1 and P4 primers to 
verify the integration of the recombinant L-Ag85B fusion gene. 
 
 
Expression of the L-Ag85B fusion protein in recombinant P. 
pastoris GS115 
 
Expression experiments were conducted according to the 
procedure of Invitrogen’s Pichia expression manual. Positive 
transformants were inoculated into 10 ml BMGY medium (Buffered 
Methanol-complex Medium, 100 mM potassium phosphate, pH 6.0, 
13.4g/L YNB without amino acids, 20 g/L peptone, 10 g/L yeast 
extract, 0.4 mg/l biotin, and 10 g/L glycerol). The cultures were 
incubated at 30°C with constant shaking at 220 rpm until the 
OD600 reached 4-6. The cells were harvested by centrifugation 
(3000 rpm, 5 min) and were then resuspended in 100 mL BMMY 
medium (the Buffered Glycerol-complex Medium is same as BMGY, 
but with 10 g/L methanol instead of glycerol). The cultures were 
then incubated at 30°C with constant shaking at 220 rpm for 4 days. 
However, 1% methanol was added every 24 h. The cultures were 
harvested by centrifugation (7000 g, 5 min, 4°C) to analyze the 
expression of the fusion protein. Nonetheless, P. pastoris 




Analysis of protein production by SDS-PAGE and Western blot  
 
The secretory proteins in the culture supernatants were subjected 
to SDS-PAGE. Proteins were stained with 0.2% Coomassie brilliant 
blue R-250 or were transferred electrophoretically onto poly-
vinylidene fluoride transfer membranes for western blot analysis. L-
Ag85B fusion proteins were detected using monoclonal anti-HbsAg 
or anti-Ag85B antibodies. Peroxidase-conjugated goat anti-mouse 
or anti-rabbit IgG were respectively used as the secondary 
antibodies, and  in  developing  the  Western  Blots.  






Figure 1. Agarose gel electrophoresis of the HBV L PCR 
product using primers P1 and P2 (lanes 1 and 2). M: 1 Kb 




Detection of L-Ag85B fusion protein with serum samples by 
ELISA 
 
After 4 days induction of the medium containing 1% methanol, the 
supernatant was collected, and after 56.8 g/100 mL (about 85% 
saturation at 4°C) ammonium sulfate precipitation, Y-PER* 6xHis 
Fusion Protein Purification Kit was then used to purify the protein. 
The purified protein L-Ag85B was used as coating antigen. In the 
serum samples, anti-HBsAg positive serum (convalescent hepatitis 
B patients) and anti-Ag85B serum (suspected TB patients) were 
used as the antibody sources. At the same time, the blank (saline) 
and healthy human serum was set as a negative control, while the 
mouse anti-HbsAg monoclonal antibody and rabbit anti-Ag85B 
monoclonal antibody was set as a positive control. Serum samples 
were diluted at 1:50, 1:100 and 1:200. When the samples were 
assayed at 450 nm with a microplate reader, the test OD value of 
every well was used to determine the level of serum antibody. 
Consequently, all experiments were performed in triplicate. When 
the OD values of the samples were more than 2.1 times as a 





Amplification of HBV L and MTB Ag85B gene by PCR 
 
We used the HBV genome extracted from HBsAg 
positive serum and the genome of MTB H37Rv as 
templates to amplify the HBV L gene and the MTB Ag85B 
gene, respectively. Agarose gel electrophoresis showed 
that the size of the PCR products was about 1200 and 







Figure 2. Agarose gel electrophoresis of the PCR product 
of Ag85B gene, using primers P3 and P4 (lanes 1 and 2). 
Ag85B gene PCR products are same with those 




Colony PCR of pPICZαC-L-Ag85B plasmids 
 
We used pPICZαC-L-Ag85B as a template, and P1 and 
P4 as primers to amplify L-Ag85B gene by PCR. As such, 
the agarose gel electrophoresis showed that the size of 
the PCR product was about 2060 bp in specific fragment, 
and the results were in conformity with the anticipated 
fragment (Figure 3). 
 
 
pPICZαC-L-Ag85B plasmids detection by double 
restriction enzyme digestion 
 
pPICZαC-L-Ag85B Plasmids were double digested by 
EcoRI and KpnI, and the agarose gel electrophoresis 
showed 2060 (L-Ag85B fusion gene) and 3600 bp 







Figure 3. Agarose gel electrophoresis of the PCR 
product of L-Ag85B gene, using primers P1 and P4 at 
annealing temperature of 56°C. Lanes 1 and 2: L-
Ag85B gene PCR products are same with those 




Sequencing identification of pPICZαC-L-Ag85B 
plasmids 
 
The insertion of the recombinant plasmid pPICZαC-L-
Ag85B was checked by sequencing, and the results 
showed that it was the same as reported by HBV L gene 
(GI: 157091234) and MTB Ag85B gene (GI: 6469794) 
sequences. It showed that the recombinant plasmid 
pPICZαC-L-Ag85B was successfully constructed. 
 
 
Identification of recombinant yeast by PCR 
 
We extracted yeast genomic DNA taken as a template for 
PCR with primers P1 and P4 to confirm the integration of 
L-Ag85B. A 2060 bp PCR product was detected in 
positive transformants. By agarose gel electrophoresis, 
the result was in agreement with L-Ag85B fragment. L-
Ag85B was correctly integrated into the P. pastoris 
genome, which is desirable for the stable fusion protein 
production (Figure 5). 
 
 
Assay of the protein recombinant yeast by SDS-
PAGE and Western blot 
 
SDS-PAGE analysis with the culture supernatants 
showed that the recombinant protein secreted from P. 
pastoris GS115 had a molecular weight of 78 KD (Figure 
6). We detected the fusion protein by Western blot 
analysis, and it was proved that the protein can produce 






Figure 4. Agarose gel electrophoresis of 
the double digestion of pPICZαC-L-
Ag85B with EcoRI and KpnI. Lanes 1 and 
2: Two specific fragments, 2060 bp of L-
Ag85B fusion gene and 3600 bp of 





specific reaction with Mouse anti-human HbsAg\Ag85B 
monoclonal antibody (Figures 7 and 8). 
 
 
Results of L-Ag85B fusion protein with serum 
samples by ELISA 
 
The purified protein L-Ag85B was used as coating 
antigen (Figure 9). When serum samples were diluted at 
1:50, the test results for 8 cases of anti-HBsAg positive 
serum of convalescent HB patients were all positive; at 
1:100, 3 cases of serum were weakly positive, while 
others were negative; and at 1:200, all the cases were 
negative.  
 When the serum samples were diluted at 1:50, the 
results for 2 out of 8 cases of serum with suspected 
tuberculosis patients were weakly positive, while others 
were positive, but at 1:100 and 1:200 fold dilution, the 
results for all samples of serum were negative. The 
results show that the purified L-Ag85B fusion protein 
could maintain the specific immunoreactivity with anti-





In recent years, series of problems have arisen in pre-
venting various infectious diseases, such as higher 
frequency of children vaccination, more difficulties in 
vaccine   management,  greater  cost  of  vaccination, etc  






Figure 5. Agarose gel electrophoresis of the PCR 
product of L-Ag85B gene, using primers P1 and P4, at 
annealing temperature of 56°C for the identification of 
the recombinant yeast cells. Lane 1: PCR products 
from P. pastoris GS115 genomic DNA; lane 2: 1 Kb 
DNA marker; lanes 3 and 4: L-Ag85B gene PCR 




(Wang and Hu, 2007; Yang et al., 2006). Therefore, it is 
imperative to develop and promote the application of a 
combined vaccine which can prevent various diseases 
(Einer-Jensen et al., 2009; Jing et al., 2002; Jin et al., 
2006). Currently, the main component of the combined 
vaccine of HBV and TB are HBsAg and BCG. The 
combined vaccine is a hybrid solution, containing the 
engineering recombinant HBV vaccine and the 
attenuated BCG vaccine (Jin et al., 2006). The combined 
vaccine of HBV and TB is safe, but there are also defects 
of immunogenicity affecting its preventive effect. In 
addition, the hybrid solution of the two vaccines needs 
improvement, in its stability, dosage, prescription design 
and production costs, which has not been widely used in 
China. Scientists all over the world are still committed to 
developing new types of HBV-TB combined vaccine. 
The HBV genome contains four ORFs, called S, C, P 
and X region. The S gene region includes three ATG 
initiation codons: PreS1, PreS2 and S segments, 
encoding three kinds of surface antigen protein. S protein 
is translated by the S region, M protein by the PreS2 and 







Figure 6. SDS-PAGE of the L-Ag85B fusion 
protein. A specific fragment of 78 KD was 
produced only in the recombinant yeast 
strain. Lane 1: The sample of the 
supernatant of P. pastoris GS115; lane 2: 
The sample of the supernatant of 







Figure 7. Western-blot of the L-Ag85B fusion protein 
probed with an HbsAg monoclonal antibody. Lanes 1 and 
2: Lysate supernatant from the recombinant P. pastoris 




regions (Young et al., 2001). Thus, when the L and S 
protein were compared, the L protein has PreS1 and 
PreS2. The 21-47aa of PreS1 act as the liver cell 
receptor binding site and the PreS1 peptide has many T 
cells and B cell epitopes, the immunogenicity of which is 
stronger than the S protein (Le Seyec et al., 1999; 
Cruciani et al., 2007; Rizza et al., 2002). The PreS2 (120-
145aa) sequence also contains multiple epitopes and 
neutralizing sites of viruses. The vaccine preparation, 
when joined by PreS1 and PreS2 epitopes, can induce 







Figure 8. Western-blot of the L-Ag85B fusion protein 
probed with Ag85B monoclonal antibody. Lane 1: 
Lysate supernatant of P. pastoris GS115; lanes 2 and 





against HBV, protect organs against viruses, break 
immune tolerance and clear HBV. Moreover, the 
frequency of non-response or low-response to traditional 
vaccine could be greatly reduced (Sasaki et al., 2003; Pol 
et al., 2001). 
Ag85B is a major early secreted protein of M. 
tuberculosis and BCG is a major protective antigen of M. 
tuberculosis. With nine immunodominant, Ag85B can 
induce a high level of specificity of the antibody response 
and the Th1-type cellular immune response (Skinner et 
al., 2003; Kariyone et al., 2003; Dietrich et al., 2006). It 
also has specific T cell recognition sites, which stimulate 
the production of memory T cells, promote cytokine 
secretion and enhance the activity of CTL (Elvang et al., 
2009; Triccas et al., 2002). In addition, Ag85B protein 
easily binds human fibrin and promotes phagocyte M. 
tuberculosis, which thus plays a stronger role in the 
prevention of tuberculosis re-infection (Sinha et al., 
1997). Studies show that the vaccines containing Ag85B 
gene enhance the immune effect of BCG (Skinner et al., 
2003) and induce a stronger CTL activity (Zhang et al., 
2006). More and more researches focus on the function 
of Ag58B, in that it is now used in human trials (Van 
Dissel et al., 2010). In this sense, Ag85B could be seen 
as an important antigen candidate for TB vaccine. 
Pentapeptide as a linker, composed of glycine and 
serine (G-S-G-G-S), is added to the upstream primer of 
MTB Ag85B gene. The purpose of adding the linker to 
the fusion proteins is to make HBV L protein and Ag85B 
fold the best in their natural 3D structures and to prevent 
their intrinsic immunogenicity (Gustavsson et al., 2001). 
In studying the character of the fusion protein, the 
recombinant plasmid is transformed into P. pastoris 
GS115, and the expression of the L-Ag85B fusion protein 
is determined by SDS-PAGE and Western blot. 
In recent years, P. pastoris has been developed quickly 
as one of the most important expression systems 
(Gellissen, 2000). This is due to the large scale of 
production of recombinant proteins with high expression 
levels and inexpensive growth media. Pichia is capable of 
performing posttranslational modifications such as 
glycosylation and proteolytic processing that aremore 
similar   to  human  protein  modifications.  It  is  easier  to 






Figure 9. SDS-PAGE of the purified 
protein L-Ag85B. A specific fragment 
of 78 KD was produced only in the 
recombinant yeast strain. Lane 1: the 
purified protein L-Ag85B of the 
recombinant P. pastoris GS115; lane 
2: the purified supernatant of P. 





purify heterologous proteins because P. pastoris releases 
few of its own proteins into the culture medium 
comparatively (Li et al., 2010). pPICZαC which is a yeast 
secretive expression vector, with a strong secretion 
signal peptide α-factor, can guide the protein secretion to 
extracellular, increase the production of foreign proteins 
and simplify its purification process. 
In this study, hepatitis B L gene and tuberculosis 
Ag85B gene combined vaccines are successfully 
constructed and the fusion protein is expressed in P. 
pastoris GS115. Using the fusion gene in P. pastoris 
expression, a higher stability of the protein which can be 
modified for effective processing can be obtained. 
Detection of the purified L-Ag85B fusion protein with anti-
HBsAg positive serum and anti-Ag85B positive serum by 
ELISA thereby provide a preliminary proof of the fusion 
protein that can maintain the specific immunoreactivity. In 
conclusion, this study successfully constructed the yeast 
expression system to the expression of L-Ag85B fusion 
protein, and provided a basis for the further study of 
hepatitis B and tuberculosis combined vaccine 
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